El tratamiento broncodilatador en la prevención de las exacerbaciones de la EPOC

  1. P. Sobradillo Ecenarro 2
  2. J.L. García-Rivero 1
  3. J.C. López Caro 3
  1. 1 Servicio de Neumología, Hospital de Laredo, Laredo, Cantabria, España
  2. 2 Servicio de Neumología, Hospital Universitario de Cruces, Baracaldo, Vizcaya, España
  3. 3 Centro de Salud Cotolino, Castro Urdiales, Cantabria, España
Erakutsi afiliazioak +
Aldizkaria:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Argitalpen urtea: 2019

Zenbakia: 7

Orrialdeak: 479-488

Mota: Artikulua

DOI: 10.1016/J.SEMERG.2019.03.009 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Semergen: revista española de medicina de familia

Garapen Iraunkorreko Helburuak

Laburpena

The natural course of chronic obstructive pulmonary disease usually includes exacerbations. chronic obstructive pulmonary disease patients suffer from 1-4 exacerbations per year on average. These are associated with worsening quality of life and increased mortality. Reducing and controlling the number of exacerbations is one of the main goals of chronic obstructive pulmonary disease treatment. Among current treatments, tiotropium is the active substance with the strongest evidence in the reduction of moderate/severe exacerbations, together with a good safety and tolerability profile. The addition of olodaterol to tiotropium offers well-tolerated and effective double bronchodilation for improving lung function, quality of life, and decreased dyspnoea compared to its single components. This also reduces the annual rate of moderate/severe exacerbations vs. tiotropium by 7%, although not reaching the pre-specified statistical significance level of P<.01.

Erreferentzia bibliografikoak

  • M. Calle Rubio, B.M. Chacón, J.L. Rodríguez Hermosa Exacerbación de la EPOC Arch. Bronconeumol., 46 (2010), pp. 21-25 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • K.R. Chapmann, et al. Epidemiology and costs of chronic obstructive pulmonary disease Eur. Respir. J., 27 (2006), pp. 188-207 View Record in ScopusGoogle Scholar
  • J.A. Wedzicha, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am. J. Respir. Crit. Care Med., 177 (2008), pp. 19-26 CrossRefView Record in ScopusGoogle Scholar
  • Ministerio de Sanidad Servicios Sociales e Igualdad. Guía de Práctica Clínica para el Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC).(GRAFO, S.A., 2012). Google Scholar
  • G.C. Donaldson, T.A.R. Seemungal, A. Bhowmik, J.A. Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax, 57 (2002), pp. 847-852 View Record in ScopusGoogle Scholar
  • M.L. Decramer, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study Lancet. Respir. Med., 1 (2013), pp. 524-533 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.A. Durlak, R.P. Weissberg, A.B. Dymnicki, R.D. Taylor, K.B. Schellinger The impact of enhancing students’ social and emotional learning: A meta-analysis of school-based universal interventions Child Dev., 82 (2011), pp. 405-432 CrossRefView Record in ScopusGoogle Scholar
  • J.J. Soler-Cataluña, M.Á. Martínez-García, P.C. Serra Impacto multidimensional de las exacerbaciones de la EPOC Arch. Bronconeumol., 46 (2010), pp. 12-19 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • I.D. Pavord, P.W. Jones, K.F. Burgel P.R & Rabe Exacerbations of COPD. Int. J. Chron. Obstruct Pulmon. Dis. Ip (2016) doi:10.2147/COPD.S85978 Google Scholar
  • M. Miravitlles, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017 Tratamiento farmacológico en fase estable Arch. Bronconeumol., 53 (2017), pp. 324-335 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Esteban, et al. Predictors of mortality in patients with stable COPD J. Gen. Intern. Med., 23 (2008), pp. 1829-1834 CrossRefView Record in ScopusGoogle Scholar
  • J.J. Soler-Cataluña, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax, 60 (2005), pp. 925-931 CrossRefView Record in ScopusGoogle Scholar
  • J. Soler-Cataluña, M. Martinez-Garcia, L. Sanchez, M. Tordera, P. Sanchez Severe exacerbations and BODE index: Two independent risk factors for death in mate COPD patients Respir. Med., 103 (2009), pp. 692-699 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease - 2019 Report. Glob. Initiat. Chronic Obstr. Lung Dis. Inc (2019). doi:10.1109/EDPC. 2012.6425109. Google Scholar
  • M. Miravitlles, et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities Thorax (2009) doi:10.1136/thx.2009.115725 Google Scholar
  • I. Alfageme, et al. Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN Arch. Bronconeumol., 55 (2018), pp. 38-47 Google Scholar
  • J.R. Hurst, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease N. Engl. J. Med., 363 (2010), pp. 1128-1138 View Record in ScopusGoogle Scholar
  • M. Santibáñez, et al. Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease PLoS One, 11 (2016), p. e0158727 CrossRefView Record in ScopusGoogle Scholar
  • M. Miravitlles, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study Thorax, 59 (2004), pp. 387-395 View Record in ScopusGoogle Scholar
  • D.P. Tashkin, C.B. Cooper The role of long-acting bronchodilators in the management of stable COPD Chest, 125 (2004), pp. 249-259 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Brusasco, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax, 58 (2003), pp. 399-404 View Record in ScopusGoogle Scholar
  • D.P. Tashkin, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N. Engl. J. Med., 359 (2008), pp. 1543-1554 View Record in ScopusGoogle Scholar
  • M. Decramer, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet, 374 (2009), pp. 1171-1178 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Tantucci, D. Modina Lung function decline in COPD Int. J. Chron. Obstruct. Pulmon. Dis., 7 (2012), pp. 95-99 CrossRefView Record in ScopusGoogle Scholar
  • C. Vogelmeier, et al. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD N. Engl. J. Med., 364 (2011), pp. 1093-1103 CrossRefView Record in ScopusGoogle Scholar
  • T. Welte, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med., 180 (2009), pp. 741-750 View Record in ScopusGoogle Scholar
  • S.D. Aaron, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann. Intern. Med., 146 (2007), pp. 545-555 CrossRefView Record in ScopusGoogle Scholar
  • C. Karner, C.J. Cates The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease Cochrane database Syst. Rev. CD009039 (2011) doi:10.1002/14651858.CD009039.pub2 Google Scholar
  • D. Singh, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial Lancet, 388 (2016), pp. 963-973 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.A. Lipson, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD N. Engl. J. Med. NEJMoa1713901 (2018) doi:10.1056/NEJMoa1713901 Google Scholar
  • A. Papi, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial Lancet, 391 (2018), pp. 1076-1084 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.A. Wedzicha, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Eur. Respir. J., 50 (2017), p. 1602265 CrossRefGoogle Scholar
  • J.A. Wedzicha, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study Lancet Respir. Med., 1 (2013), pp. 199-209 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • K. Beeh, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med., 196 (2017), pp. 139-149 CrossRefView Record in ScopusGoogle Scholar
  • M. Decramer, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials Lancet. Respir. Med., 2 (2014), pp. 472-486 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.R. Maleki-Yazdi, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial Respir. Med., 108 (2014), pp. 1752-1760 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.M.A. Calverley, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial The Lancet Respiratory Medicine (2018), 10.1016/S2213-2600(18)30102-4 Google Scholar
  • J.A. Wedzicha, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD N. Engl. J. Med., 374 (2016), pp. 2222-2234 CrossRefView Record in ScopusGoogle Scholar
  • N. Horita, N. Miyazawa, K. Tomaru, M. Inoue, T. Kaneko Long-acting muscarinic antagonist-+-long-acting beta agonist versus long-acting beta agonist-+-inhaled corticosteroid for COPD: A systematic review and meta-analysis Respirology, 20 (2015), pp. 1153-1159 CrossRefView Record in ScopusGoogle Scholar
  • D.A. Lipson, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med., 196 (2017), pp. 438-446 CrossRefView Record in ScopusGoogle Scholar
  • H. Magnussen, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD N. Engl. J. Med., 371 (2014), pp. 1285-1294 CrossRefView Record in ScopusGoogle Scholar
  • H. Watz, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial Lancet Respir. Med., 4 (2016), pp. 390-398 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Suissa, J.M. Drazen Making Sense of Triple Inhaled Therapy for COPD N. Engl. J. Med. NEJMe1716802 (2018), 10.1056/NEJMe1716802 Google Scholar
  • A. Agusti Filling the gaps in COPD: the TRIBUTE study The Lancet, 391 (2018), pp. 1004-1006 ArticleDownload PDFView Record in ScopusGoogle Scholar
Datuen iturria: Dialnet